ESR1 and breast carcinoma: Remarkably, among the patients with ER-positive, HER2-positive breast cancer, those with low ER expression or high HER2 expression alongside elevated TIL levels exhibited response rates comparable to patients with ER-negative, HER2-positive breast cancer.